DK1414996T3 - Fremgangsmåder til genetisk modifikation af hæmatopoetiske progenitorceller og anvendelser af modificerede celler - Google Patents

Fremgangsmåder til genetisk modifikation af hæmatopoetiske progenitorceller og anvendelser af modificerede celler

Info

Publication number
DK1414996T3
DK1414996T3 DK02746963.4T DK02746963T DK1414996T3 DK 1414996 T3 DK1414996 T3 DK 1414996T3 DK 02746963 T DK02746963 T DK 02746963T DK 1414996 T3 DK1414996 T3 DK 1414996T3
Authority
DK
Denmark
Prior art keywords
cells
methods
hematopoietic progenitor
genetically modifying
modified
Prior art date
Application number
DK02746963.4T
Other languages
English (en)
Inventor
Geoffery P Symonds
Rafael Amado
Lun-Quan Sun
Janet Macpherson
Greg Fanning
Wayne Gerlach
Original Assignee
Johnson & Johnson Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Res Pty Ltd filed Critical Johnson & Johnson Res Pty Ltd
Application granted granted Critical
Publication of DK1414996T3 publication Critical patent/DK1414996T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK02746963.4T 2001-07-10 2002-07-10 Fremgangsmåder til genetisk modifikation af hæmatopoetiske progenitorceller og anvendelser af modificerede celler DK1414996T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30412701P 2001-07-10 2001-07-10
US30428301P 2001-07-10 2001-07-10
US34348401P 2001-12-21 2001-12-21
US38606302P 2002-06-04 2002-06-04
PCT/US2002/021907 WO2003006691A1 (en) 2001-07-10 2002-07-10 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells

Publications (1)

Publication Number Publication Date
DK1414996T3 true DK1414996T3 (da) 2011-03-21

Family

ID=27501852

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02746963.4T DK1414996T3 (da) 2001-07-10 2002-07-10 Fremgangsmåder til genetisk modifikation af hæmatopoetiske progenitorceller og anvendelser af modificerede celler

Country Status (16)

Country Link
US (2) US7345025B2 (da)
EP (2) EP1414996B1 (da)
JP (2) JP5179697B2 (da)
KR (1) KR101015913B1 (da)
CN (2) CN101926824A (da)
AT (1) ATE490322T1 (da)
AU (1) AU2002316640C1 (da)
BR (1) BR0211079A (da)
CA (1) CA2453531A1 (da)
DE (1) DE60238486D1 (da)
DK (1) DK1414996T3 (da)
HK (1) HK1065074A1 (da)
IL (2) IL159637A0 (da)
MX (1) MXPA04000268A (da)
NZ (1) NZ530624A (da)
WO (1) WO2003006691A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
CA2279669A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
AU2002316640C1 (en) 2001-07-10 2009-01-29 Johnson & Johnson Research Pty Limited Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
CN1551728A (zh) * 2001-07-10 2004-12-01 J&J�о��ع����޹�˾ 转导造血祖细胞的生成
US7737124B2 (en) * 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
ATE439041T1 (de) * 2001-09-13 2009-08-15 California Inst Of Techn Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle
DE10212892A1 (de) * 2002-03-20 2003-10-09 Basf Plant Science Gmbh Konstrukte und Verfahren zur Regulation der Genexpression
DE10224750A1 (de) 2002-06-04 2003-12-24 Fresenius Medical Care De Gmbh Vorrichtung zur Behandlung einer medizinischen Flüssigkeit
WO2004071418A2 (en) * 2003-02-06 2004-08-26 Walter Reed Army Institute Of Research Compounds for the treatment of systemic lupus erythematosus
WO2004090121A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
GB0410130D0 (en) * 2004-05-06 2004-06-09 Molmed Spa Cell preparation
US7935074B2 (en) * 2005-02-28 2011-05-03 Fresenius Medical Care Holdings, Inc. Cassette system for peritoneal dialysis machine
US8197231B2 (en) 2005-07-13 2012-06-12 Purity Solutions Llc Diaphragm pump and related methods
ATE525460T1 (de) * 2005-07-20 2011-10-15 Seoul Nat Univ Ind Foundation Verfahren zur kultivierung und vermehrung hämatopoetischer stammzellen und vorläuferzellen unter verwendung menschlicher endometriumzellen
EP2032691A2 (en) * 2006-06-15 2009-03-11 Neostem, Inc Processing procedure for peripheral blood stem cells
JP2011160661A (ja) * 2008-06-02 2011-08-25 Kyowa Hakko Kirin Co Ltd 血球細胞の初期化法
US8112365B2 (en) * 2008-12-19 2012-02-07 Foster Scott C System and method for online employment recruiting and evaluation
US20100210989A1 (en) 2008-12-23 2010-08-19 Janet Lesley Macpherson Processing blood
US8192401B2 (en) 2009-03-20 2012-06-05 Fresenius Medical Care Holdings, Inc. Medical fluid pump systems and related components and methods
US20120034197A1 (en) * 2009-04-09 2012-02-09 Stemcyte Inc. Hiv-resistant stem cells and uses thereof
CA2767668C (en) 2009-07-15 2017-03-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US8720913B2 (en) 2009-08-11 2014-05-13 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis carts and related systems
EP2647697B1 (en) * 2010-12-01 2016-08-24 Nissan Chemical Industries, Ltd. Method for producing hematopoietic stem cells using pyrazole compound
DE102010053973A1 (de) 2010-12-09 2012-06-14 Fresenius Medical Care Deutschland Gmbh Medizinisches Gerät mit einer Heizung
EP2654825B1 (en) 2010-12-20 2017-08-02 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9624915B2 (en) 2011-03-09 2017-04-18 Fresenius Medical Care Holdings, Inc. Medical fluid delivery sets and related systems and methods
AU2012254069B2 (en) 2011-04-21 2015-10-08 Fresenius Medical Care Holdings, Inc. Medical fluid pumping systems and related devices and methods
US9186449B2 (en) 2011-11-01 2015-11-17 Fresenius Medical Care Holdings, Inc. Dialysis machine support assemblies and related systems and methods
US9610392B2 (en) 2012-06-08 2017-04-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9500188B2 (en) 2012-06-11 2016-11-22 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
JP6283031B2 (ja) * 2012-09-07 2018-02-21 イエール ユニバーシティ 遺伝学的に修飾された非ヒト動物およびその使用法
RU2673156C2 (ru) * 2012-11-05 2018-11-22 Ридженерон Фармасьютикалз, Инк. Генетически модифицированные не относящиеся к человеческому роду животные и способы их применения
US10077426B2 (en) * 2012-12-06 2018-09-18 Enlivex Therapeutics Ltd Therapeutic apoptotic cell preparations, method for producing same and uses thereof
US9561323B2 (en) 2013-03-14 2017-02-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassette leak detection methods and devices
US10117985B2 (en) 2013-08-21 2018-11-06 Fresenius Medical Care Holdings, Inc. Determining a volume of medical fluid pumped into or out of a medical fluid cassette
CN103471896A (zh) * 2013-09-09 2013-12-25 上海兰卫临床检验有限公司 革兰染色液质控品制备方法
WO2018201065A1 (en) * 2017-04-27 2018-11-01 Fred Hutchinson Cancer Research Center Therapeutic formulations containing cd34+ stem cells derived from negative selection
CN111417407A (zh) * 2017-11-15 2020-07-14 奇异科学有限责任公司 用于非清髓性骨髓重建的方法和组合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
RO114469B1 (ro) 1987-12-15 1999-04-30 Gene Shears Pty Ltd Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare
US5866701A (en) 1988-09-20 1999-02-02 The Board Of Regents For Northern Illinois University Of Dekalb HIV targeted hairpin ribozymes
US4978514A (en) 1989-09-12 1990-12-18 Fuel Tech, Inc. Combined catalytic/non-catalytic process for nitrogen oxides reduction
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5500357A (en) 1990-11-02 1996-03-19 Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry RNA transcription system using novel ribozyme
CA2107789A1 (en) 1991-04-05 1992-10-06 Thomas E. Wagner Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences
US5693535A (en) 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5525468A (en) 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
RU94046396A (ru) 1992-06-29 1996-11-10 Джин Ширс Пти.Лтд. (AU) Нуклеиновая кислота, днк, вектор, способ получения растения или животного, способ получения клеток, способ создания животного, животное, трансгенное животное, трансгенное растение, плоды, черенки и семена, растительные клетки, способ вмешательства в репликацию вируса
AU5961994A (en) 1993-01-22 1994-08-15 University Research Corporation Localization of therapeutic agents
IL108719A0 (en) 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
WO1995004818A1 (en) 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
ATE320487T1 (de) 1994-01-05 2006-04-15 Gene Shears Pty Ltd Ribozyme gegen eine hiv tat sequenz
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US20020058636A1 (en) 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
WO1996033281A1 (en) 1995-04-20 1996-10-24 Chiron Corporation High efficiency ex vivo transduction of hematopoietic stem cells by recombinant retroviral preparations
US5741706A (en) * 1996-06-13 1998-04-21 Immusol, Incorporated Anti-HIV ribozymes
TWI239352B (en) 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6060317A (en) 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto
WO2000034495A2 (en) * 1998-12-04 2000-06-15 City Of Hope A method of genetically modifying very primitive quiescent human hematopoietic stem cells
WO2000075291A2 (en) * 1999-06-08 2000-12-14 Novartis Ag Cells with enforced expression of bcl-xl
ATE510837T1 (de) 2000-09-13 2011-06-15 Vertex Pharma Caspase inhibitoren und deren verwendung
EP1354038A2 (en) 2000-12-28 2003-10-22 J & J Research Pty Ltd Double-stranded rna-mediated gene suppression
AU2002316640C1 (en) 2001-07-10 2009-01-29 Johnson & Johnson Research Pty Limited Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
CN1551728A (zh) * 2001-07-10 2004-12-01 J&J�о��ع����޹�˾ 转导造血祖细胞的生成
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
KR100646702B1 (ko) * 2001-08-16 2006-11-17 에스케이씨 주식회사 홀 및/또는 그루브로 형성된 화학적 기계적 연마패드

Also Published As

Publication number Publication date
US7776595B2 (en) 2010-08-17
US7345025B2 (en) 2008-03-18
ATE490322T1 (de) 2010-12-15
CN1553963A (zh) 2004-12-08
IL159637A0 (en) 2004-06-01
US20040072771A1 (en) 2004-04-15
NZ530624A (en) 2009-02-28
BR0211079A (pt) 2005-08-30
WO2003006691A1 (en) 2003-01-23
KR20040032852A (ko) 2004-04-17
KR101015913B1 (ko) 2011-02-23
EP1414996A4 (en) 2007-03-28
EP1414996A1 (en) 2004-05-06
HK1065074A1 (en) 2005-02-08
EP2322618A1 (en) 2011-05-18
EP1414996B1 (en) 2010-12-01
AU2002316640B2 (en) 2008-06-12
AU2002316640C1 (en) 2009-01-29
JP2005528319A (ja) 2005-09-22
CN101926824A (zh) 2010-12-29
DE60238486D1 (de) 2011-01-13
JP2010077125A (ja) 2010-04-08
JP5179697B2 (ja) 2013-04-10
MXPA04000268A (es) 2005-03-07
IL159637A (en) 2013-07-31
CA2453531A1 (en) 2003-01-23
US20080044394A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
DK1414996T3 (da) Fremgangsmåder til genetisk modifikation af hæmatopoetiske progenitorceller og anvendelser af modificerede celler
DK1196444T3 (da) Exendin-4-konjugater og deres medicinske anvendelighed
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
WO2002064096A3 (en) Methods of using pyrimidine-based antiviral agents
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
MY129263A (en) Vaccine composition
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
DE60229848D1 (de) - und organtransplantationen und unterdrückt apoptose
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
WO2006050058A3 (en) Methods of detection and therapy of inflamed tissues using immune modulation
DK1163904T3 (da) Sammensætning til forebyggelse af glat muskelsygdom, der omfatter ascorbat, arginin og magnesium
DK1237549T3 (da) Lipoxin A4 og dets analoger til behandling af törre öjne
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2004087086A3 (de) Leistungsfähige oxidative haarbehandlungsmittel mit faserstrukturstabilisierung durch radikalfänger
DE60335647D1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
WO2003037168A3 (en) Methods and formulations for minimizing spasticity in blood vessel grafts
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
DK1372669T3 (da) Bisphosphonatholding sammensætning til forebyggelse og/eller behandling af metaboliske knoglesygdomme, fremgangsmåde til fremstilling af sådanne sammensætninger og anvendelse deraf
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
WO2004009029A3 (en) Compositions and methods for treating and preventing infection
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
TR201910060T4 (tr) SYN3 bileşimleri ve yöntemleri.